胃泌素释放肽前体在小细胞肺癌中的表达水平及其意义

Expression of Pro-gastrin-releasing Peptide in Small Cell Lung Cancer and Its Significance

目的探讨胃泌素释放肽前体(ProGRP)在小细胞肺癌(SCLC)中的表达水平及临床意义。方法选择2011年5月—2013年5月安徽医科大学第一附属医院收治的初诊SCLC患者88例为SCLC组、非SCLC患者84例为NSCLC组、肺部良性病变患者50例为良性病变组,另选择同期在本院行体检健康者40例为对照组。采用ELISA法检测受试者血清ProGRP水平;采用放射免疫法检测血清神经元特异性烯醇化酶(NSE)水平。结果 4组血清ProGRP和NSE水平比较,差异均有统计学意义(P<0.05),其中SCLC组和NSCLC组血清ProGRP和NSE水平均高于对照组和良性病变组(P<0.05);SCLC组血清ProGRP和NSE水平均高于NSCLC组(P<0.05)。SCLC广泛期血清ProGRP和NSE水平均高于SCLC局限期(t=18.483、10.959,P<0.05)。治疗前SCLC缓解期、好转期和进展期ProGRP水平比较,差异无统计学意义(P>0.05);治疗后SCLC缓解期、好转期和进展期ProGRP水平比较,差异有统计学意义(P<0.05),其中进展期ProGRP水平均高于缓解期和好转期(P<0.05)。缓解期、好转期治疗后ProGRP水平均低于治疗前,进展期ProGRP水平治疗后高于治疗前(P<0.05)。结论血清ProGRP在SCLC中表达水平升高,尤其是进展期和广泛期;ProGRP在肿瘤的分期及预后判定有一定的临床价值。

Objective To investigate the expression of pro-gastrin-releasing peptide（ ProGRP） in small cell lung cancer（ SCLC） and its significance. Methods Patients who were admitted to the First Affiliated Hospital of Anhui Medical University from May 2011 to May 2013 were selected as study subjects,88 newly diagnosed SCLC patients were included in SCLC group,84 patients without SCLC were included in NSCLC group,50 patients with benign lung disease were included in benign lesion group,and 40 healthy examinees in the same hospital during the same period were included in control group. Serum level of ProGRP was measured by ELISA,and serum level of neuron- specific enolase（ NSE） was measured by radioimmunoassay.Results There were significant differences in serum levels of ProGRP and NSE among 4 groups（ P 〈0. 05）. The serum levels of ProGRP and NSE in SCLC group and NSCLC group were significantly higher than those in control group and benign lesion group（ P 〈0.05）. The serum levels of ProGRP and NSE in SCLC group were significantly higher than those in NSCLC group（ P 〈0. 05）. The serum levels of ProGRP and NSE among SCLC patients in extended stage were significantly higher than those in limited stage（ t = 18. 483,10. 959,P 〈0. 05）. Before treatment,there was no significant difference in ProGRP level of SCLC patients among remission stage,resolving stage and progressive stage（ P 〈0. 05）. After treatment,there was significant difference in ProGRP level of SCLC patients among remission stage,resolving stage and progressive stage（ P 〈0. 05）,ProGRP level in progressive stage was significantly higher than that in remission stage and in resolving stage,respectively（ P 〈0. 05）. In remission stage and resolving stage,ProGRP level after treatment was significantly lower than that before treatment（ P 〈0. 05）. In progressive stage,ProGRP level after treatment was significantly lower than that before treatment（ P 〈0. 05）. Conclusion Serum ProGRP level is high among SCLC patients,especially among SCLC patients in extended stage and in progressive stage.ProGRP provides clinical value to the tumor staging and prognosis judgement.